Which of the following is a 3A4 substrate?

Which of the following is a 3A4 substrate?

• A. Ticagrelor
• B. Amiodarone
• C. Statins
• D. All of the above

Answer: (D)

The correct answer is that all of the listed options are indeed substrates of the CYP3A4 enzyme, which plays a crucial role in the metabolism of many drugs. Ticagrelor is an antiplatelet medication that is metabolized through the CYP3A4 pathway, making it effective in preventing blood clots. The presence of the CYP3A4 enzyme is significant because any interaction with other drugs that inhibit or induce this enzyme can lead to altered levels of ticagrelor in the body, which can affect its therapeutic efficacy. Amiodarone, an antiarrhythmic agent, is another drug that is also metabolized by CYP3A4. Its metabolism can impact its dosing and effectiveness, particularly when other medications are administered that could alter the activity of this enzyme. Statins, a class of lipid-lowering medications, are well-documented substrates of CYP3A4; for instance, atorvastatin and simvastatin are metabolized via this enzyme. The clinical significance of this metabolism is notable since drug-drug interactions involving statins can lead to altered metabolism and increased risk of side effects, particularly muscle-related effects. Because each of these drug classes utilizes the CYP3A4 pathway, understanding

The correct answer is that all of the listed options are indeed substrates of the CYP3A4 enzyme, which plays a crucial role in the metabolism of many drugs.

Ticagrelor is an antiplatelet medication that is metabolized through the CYP3A4 pathway, making it effective in preventing blood clots. The presence of the CYP3A4 enzyme is significant because any interaction with other drugs that inhibit or induce this enzyme can lead to altered levels of ticagrelor in the body, which can affect its therapeutic efficacy.

Amiodarone, an antiarrhythmic agent, is another drug that is also metabolized by CYP3A4. Its metabolism can impact its dosing and effectiveness, particularly when other medications are administered that could alter the activity of this enzyme.

Statins, a class of lipid-lowering medications, are well-documented substrates of CYP3A4; for instance, atorvastatin and simvastatin are metabolized via this enzyme. The clinical significance of this metabolism is notable since drug-drug interactions involving statins can lead to altered metabolism and increased risk of side effects, particularly muscle-related effects.

Because each of these drug classes utilizes the CYP3A4 pathway, understanding